Hui Xie

Dr. Hui Xie


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Molecular Therapy
Verified
Journal Article
Open access
JZJia-Xiang Zhang
Jia-Xiang Zhang
PHPei-Jie Huang
Pei-Jie Huang
DWDa-Peng Wang
Da-Peng Wang
WYWen-Yu Yang
Wen-Yu Yang
JLJian Lu
Jian Lu
RWRuilan Wang
Ruilan Wang
Idiopathic pulmonary fibrosis (IPF) is a chronic, fatal lung disease characterized by progressive and non-reversible abnormal matrix deposition in lung parenchyma. Myofibroblasts origin mainly from resident fibroblasts via fibroblast-to-myofibroblast transition (FMT) are the dominant collagen-producing cells in pulmonary fibrosis. N6-methyladenosine (m6A) modification has been implicated in various biological process. However, the role of m6A modification in pulmonary fibrosis remains elusive. In this study, we reveal that m6A modification is up-regulated in bleomycin induced pulmonary fibrosis mice model, FMT-derived myofibroblasts and idiopathic pulmonary fibrosis patient lung samples. Lowering m6A level through silencing METTL3 inhibits FMT process in vitro and vivo. Mechanistically, KCNH6 is involved in m6A-regulated FMT process. m6A modification regulates the expression of KCNH6 by modulating its translation in a YTHDF1 dependent manner. Together, our study highlights the critical role of m6A modification in pulmonary fibrosis. Manipulation of m6A modification through targeting METTL3 may become a promising strategy for the treatment of pulmonary fibrosis.

6 September 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZZZhigang Zhou
Zhigang Zhou
TFtienan feng
tienan feng
YXYun Xie
Yun Xie
PHPeijie Huang
Peijie Huang
HXHui Xie
Hui Xie
RWRuilan Wang
Ruilan Wang
Sepsis is still a common critical disease with high morbidity and mortality in intensive care unit. Despite published guidelines for sepsis, development of antibiotic therapy and advanced organ support technologies, the mortality of sepsis patients is still 25% or more. It is necessary to distinguish the subtypes of sepsis, and the targeted therapy for the patients need to be explored. Platelets have various biological functions in hemostasis and thrombosis, host defense, inflammatory/immune responses and tissue repair/regeneration. Moreover, severe thrombocytopenia or sustained thrombocytopenia was closely associated with multiply organ dysfunction and higher mortality in sepsis patients. The clinical therapies for thrombocytopenia are platelet transfusion and platelet-elevating drugs. However, platelet transfusion has many defects in clinical practice in sepsis patients, and the impact of platelet-elevating drugs for sepsis patients is still unclear. RESCUE trial is aim to explore the effect of a platelet-elevating drug, recombinant human thrombopoietin (rhTPO), as an effective rescue therapy on sepsis patients with acute severe thrombocytopenia. It is a randomized, open-label, multi-center, controlled trial in 5 tertiary academic hospitals including medical, surgical or general ICUs. In this study, a total of 200 sepsis patients with severe thrombocytopenia will be randomly assigned in a 1:1 ratio to the control and rhTPO group. The patients will be followed up to 28 days after randomization. All patients in two groups receive the same treatment based on the guideline of Surviving Sepsis Campaign. Primary outcome is 28-day mortality. Secondary outcomes are the changes of PCs, blood transfusion, biomarkers of infection and organ function, days free from advanced organ support, drug-related adverse events, the length of ICU and hospital stay. RESCUE trial is the first randomized controlled trial to explore the impact of rhTPO for severe thrombocytopenia in sepsis patients diagnosed by sepsis-3.0 standard. Furthermore, RESCUE trial results will be of significant clinical value on the targeted therapy and add clinical evidence that rhTPO is an effective rescue therapy for these sepsis patients. ClinicalTrials.gov : NCT02707497. Registered Date: March 3rd, 2016. Protocol Version 3. Protocol Date: January 25th, 2019.

31 August 2023 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
DCDaonan Chen
Daonan Chen
RWRui Wang
Rui Wang
YJYihan Jiang
Yihan Jiang
ZXZijian Xing
Zijian Xing
QSQiuyang Sheng
Qiuyang Sheng
LZLina Zhao
Lina Zhao
Objectives: Anti-thrombotic therapy is the basis of thrombosis prevention and treatment. Bleeding is the main adverse event of anti-thrombosis. Existing laboratory indicators cannot accurately reflect the real-time coagulation function. It is necessary to develop tools to dynamically evaluate the risk and benefits of anti-thrombosis to prescribe accurate anti-thrombotic therapy. Methods: The prediction model,daily prediction of bleeding risk in ICU patients treated with anti-thrombotic therapy, was built using deep learning algorithm recurrent neural networks, and the model results and performance were compared with clinicians. Results: There was no significant statistical discrepancy in the baseline. ROC curves of the four models in the validation and test set were drawn, respectively. One-layer GRU of the validation set had a larger AUC (0.9462; 95%CI, 0.9147–0.9778). Analysis was conducted in the test set, and the ROC curve showed the superiority of two layers LSTM over one-layer GRU, while the former AUC was 0.8391(95%CI, 0.7786–0.8997). One-layer GRU in the test set possessed a better specificity (sensitivity 0.5942; specificity 0.9300). The Fleiss’ k of junior clinicians, senior clinicians, and machine learning classifiers is 0.0984, 0.4562, and 0.8012, respectively. Conclusions: Recurrent neural networks were first applied for daily prediction of bleeding risk in ICU patients treated with anti-thrombotic therapy. Deep learning classifiers are more reliable and consistent than human classifiers. The machine learning classifier suggested strong reliability. The deep learning algorithm significantly outperformed human classifiers in prediction time.

29 April 2025 in Journal of Clinical Ultrasound
Verified
Journal Article
Closed access
JZJia Zhan
Jia Zhan
FLFang Li
Fang Li
JMJi Ma
Ji Ma
HXHui Xie
Hui Xie
LLLong Liu
Long Liu
RWRong Wu
Rong Wu

1 December 2025 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
JZJia Zhan
Jia Zhan
FLFang Li
Fang Li
JMJi Ma
Ji Ma
HXHui Xie
Hui Xie
LLLong Liu
Long Liu
RWRong Wu
Rong Wu
Background: Papillary thyroid cancer (PTC) patients with capsule invasion have a risk of poor clinical outcomes. The aim of this study was to assess the diagnostic accuracy of quantitative contrast-enhanced ultrasound (CEUS) for detecting capsule invasion and identifying the relationship between capsule invasion and sonographic features of PTC. Methods: Patients confirmed as having PTC underwent conventional ultrasound (US) and CEUS examinations. The conventional US and qualitative CEUS features of the PTC nodules and capsule invasion were evaluated and classified separately. The accuracy of conventional US and qualitative CEUS in predicting capsule invasion was compared separately. Moreover, quantitative parameters were analyzed in different groups. The presence or absence of capsule invasion and cervical lymph node metastasis (LNM) was confirmed by the pathological results. Results: The study finally included 107 patients with 109 PTC nodules. A total of 58 (53.2%) of PTC nodules had no capsule invasion, whereas the remaining 51 had capsule invasion [including 19 patients with extracapsular extension (ECE)]. A significant difference was found in nodules with non-capsule invasion, single capsule invasion, and ECE between the LNM and non-LNM groups (χ2=11.34, P<0.01). Single capsule invasion and ECE demonstrated a significant linear trend with cervical LNM (r=0.309, P=0.001). Independent predictive conventional US and qualitative CEUS features included nodule size, contour bulging, and capsular abutment on CEUS and discontinuous capsular enhancement on CEUS. In quantitative CEUS parameters, peak intensity (PI) was most valuable for predicting capsule invasion, and significant differences were found between the non-capsule invasion group (12.7±1.2) and the single capsule invasion group (29.2±5.2), and the non-capsule invasion group (12.7±1.2) and the ECE group (35.5±6.4). Moreover, the quantitative CEUS-assisted US equation demonstrated the best diagnostic performance compared with the conventional US and qualitative CEUS approach. Conclusions: Compared with conventional US and qualitative CEUS, quantitative CEUS is a more reliable and objective imaging method to predict capsule invasion of PTC.

14 May 2025 in Journal of Intensive Medicine
Verified
Journal Article
Open access
SJShanshan Jin
Shanshan Jin
SMShiyu Meng
Shiyu Meng
QHQiuping Huang
Qiuping Huang
HXHui Xie
Hui Xie
JZJingjing Zheng
Jingjing Zheng
RWRuilan Wang
Ruilan Wang
Critically ill patients in ICUs are highly vulnerable to infectious diseases. Early and accurate identification of pathogens is vital for initiating appropriate antimicrobial therapy. To evaluate the diagnostic effectiveness in patients with suspected infectious diseases; three different molecular technologies and conventional microbiological tests were used. A total of 97 individuals suspected of having infectious diseases were retrospectively enrolled from July 2023 to January 2024 at Shanghai General Hospital. Samples were collected for metagenomic next-generation sequencing (mNGS), droplet digital polymerase chain reaction (ddPCR), multiplex drop-off digital polymerase chain reaction (MDO-dPCR), and conventional microbiological tests (CMTs) for suspected pathogen detection. The diagnostic efficacies of the three molecular technologies and CMTs were compared, and the effects of their joint application on clinical outcomes were evaluated. Intergroup comparisons were performed using the Kruskal-Wallis test, with a P-value <0.05 considered statistically significant. Joint detection exhibited a high negative predictive value. The sensitivity of MDO-dPCR, ddPCR, and mNGS was 52.6%, 48.5%, and 96.6%, respectively; and the corresponding specificity was 72.5%, 73.3%, and 50.0%. A positive correlation was observed between pathogen copies detected using MDO-dPCR and procalcitonin (Pearson's ρ=0.21, P=0.039), acute physiology and chronic health evaluation II (Pearson's ρ=0.24, P =0.018), and sequential organ failure assessment (Pearson's ρ=0.25, P=0.012). Therapeutic regimens were adjusted in 51.5% of the patients (50/97) based on the results of the combination tests. In the present study, we highlighted the significance of molecular technologies for the early diagnosis of patients with suspected infections. These technologies can serve as a complement to CMTs and should be implemented promptly to guide clinicians in providing timely and effective anti-infective treatments. Future studies should aim to confirm these findings in large-scale clinical trials to refine diagnostic protocols, while also incorporating cost-utility analyses.